andrew armstrong, md, explains whether arv-7 is predictive of response to taxanes in mpc patients
Published 4 years ago • 39 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:29
andrew armstrong, md, provides insight as to genetic testing to be conducted in a patient with mpc
-
1:24
andrew armstrong, md, offers opinion on androgen receptor inhibitors
-
2:09
andrew armstrong, md, on determining treatment of prostate cancer with dna repair markers
-
1:40
dr. armstrong on detection of chromosomal defects in mcrpc
-
1:18
andrew armstrong, md, discusses the phase 2 stream study in pre-metastatic prostate cancer
-
3:44
treatment of parkinson’s disease at uams health
-
9:53
dr. andrew armstrong on precision medicine approaches in advanced prostate cancer
-
1:00
dr. armstrong on the utility of pamiparib and other parp inhibitors in prostate cancer
-
4:23
prostate cancer shared decision-making: how does it work?
-
54:30
andrew armstrong - prognostic, predictive, and surrogate biomarkers...
-
0:57
dr. armstrong on the utility of parp inhibitors in mutated prostate cancer
-
2:38
dr. harry l. bush, jr. - history of vascular and endovascular surgery
-
3:55
factors affecting waste clearance from the brain
-
1:25
guide wire algorithm video: value of platforms for peripheral interventions (us)
-
1:08
endpoints beyond os for prostate cancer
-
2:21
meet andrew armstrong, rn
-
1:38
the neuropathology and genetics of als and ftd
-
0:31
understanding male urinary problems: common causes
-
4:19
the biology of prostate cancer